Epigenetic Checkpoints Regulate the Fate and Function of CAR-T Cells

Overview

Journal Nat Immunol

Date 2024 Jan 3

PMID 38168961

Authors

Monica Casucci

Chiara Bonini

Eliana Ruggiero

Affiliations

Soon will be listed here.

References

Jiang P, Zhang Z, Hu Y, Liang Z, Han Y, Li X . Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction. Leukemia. 2022; 36(11):2656-2668. DOI: 10.1038/s41375-022-01676-0. View

Riegel D, Romero-Fernandez E, Simon M, Adenugba A, Singer K, Mayr R . Integrated single-cell profiling dissects cell-state-specific enhancer landscapes of human tumor-infiltrating CD8 T cells. Mol Cell. 2023; 83(4):622-636.e10. DOI: 10.1016/j.molcel.2022.12.029. View

Lei A, Yu H, Lu S, Lu H, Ding X, Tan T . Author Correction: A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat Immunol. 2023; 25(3):576. DOI: 10.1038/s41590-023-01734-4. View

Tsui C, Kretschmer L, Rapelius S, Gabriel S, Chisanga D, Knopper K . MYB orchestrates T cell exhaustion and response to checkpoint inhibition. Nature. 2022; 609(7926):354-360. PMC: 9452299. DOI: 10.1038/s41586-022-05105-1. View

Locke F, Ghobadi A, Jacobson C, Miklos D, Lekakis L, Oluwole O . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2018; 20(1):31-42. PMC: 6733402. DOI: 10.1016/S1470-2045(18)30864-7. View

Qi C, Gong J, Li J, Liu D, Qin Y, Ge S . Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022; 28(6):1189-1198. PMC: 9205778. DOI: 10.1038/s41591-022-01800-8. View

Chen G, Chen C, Das R, Gao P, Chen C, Bandyopadhyay S . Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy. Cancer Discov. 2021; 11(9):2186-2199. PMC: 8419030. DOI: 10.1158/2159-8290.CD-20-1677. View

Gueguen P, Metoikidou C, Dupic T, Lawand M, Goudot C, Baulande S . Contribution of resident and circulating precursors to tumor-infiltrating CD8 T cell populations in lung cancer. Sci Immunol. 2021; 6(55). DOI: 10.1126/sciimmunol.abd5778. View

Arcangeli S, Bove C, Mezzanotte C, Camisa B, Falcone L, Manfredi F . CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Invest. 2022; 132(12). PMC: 9197529. DOI: 10.1172/JCI150807. View

10.

Melenhorst J, Chen G, Wang M, Porter D, Chen C, Collins M . Decade-long leukaemia remissions with persistence of CD4 CAR T cells. Nature. 2022; 602(7897):503-509. PMC: 9166916. DOI: 10.1038/s41586-021-04390-6. View

11.

You L, Han Q, Zhu L, Zhu Y, Bao C, Yang C . Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells. Front Immunol. 2020; 11:1787. PMC: 7461863. DOI: 10.3389/fimmu.2020.01787. View

12.

Gambacorta V, Beretta S, Ciccimarra M, Zito L, Giannetti K, Andrisani A . Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse. Cancer Discov. 2022; 12(6):1449-1461. PMC: 9394393. DOI: 10.1158/2159-8290.CD-21-0980. View